A Randomized Controlled Trial of 500 mg Oral Metronidazole Prophylactic Febrile Morbidity after Elective Abdominal Hysterectomy in Maharat Nakhon Ratchasima Hospital
Article Sidebar
Main Article Content
Abstract
Abstract:
Objective: To study the efficacy of 500 mg oral metronidazole prophylaxis in preventing febrile morbidity after elective abdominal hysterectomy.
Study design: Randomized controlled trials
Setting: Department of Obstetrics and Gynecology, Maharat Nakhon Ratchasima Hospital
Subject: Female patient admitted to the Department of Gynecology for elective abdominal hysterectomy during September 2001 and January 2002
Intervention: By randomization, 62 Patients were given a single oral dose (500 mg) of metronidazole and 62 patients received an oral placebo at least 8 hours before elective abdominal hysterectomy. All of them were undergone abdominal hysterectomy for various benign diseases. Other antibiotic use was withheld until there was no postoperative infection. Follow up postoperative febrile morbidity and other outcomes were analysed for correlation.
Main outcome measures: Mean, standard deviation, range, and Chi-square
Result: No significant differences were present in relation to age, length of hospital stay, length of operation, pathologic condition, surgeon, estimated blood loss and blood transfusion. The incidence of febrile morbidity after elective abdominal hysterectomy was 27 of 62 patients (43.5%) in the metronidazole group and 29 of 62 patients (46.8%) in the placebo group. That patients in both groups had high incidence of postoperative febrile morbidity was not statistically significant. There was low incidence of known cause of febrile morbidity, 6 of 27 patients (22.2%) in the metronidazole group and 6 of 23 patients (20.7%) in the placebo group.
Conclusion: there was no difference in the febrile morbidity rate between both groups. The results do not support the use of 500 mg oral metronidazole prophylaxis for preventing febrile morbidity after elective abdominal hysterectomy.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Calarke-Pearson DL, Olt GJ, Rodriguez GC, Boente MP. Preoperative evaluation and postoperative management. In: Berek JS, Adashi EY, Hillard PA, editors. Novak's gynecology. 12th ed. Baltimore: Williams & Wilkins;1999. p. 561-8.
Hager WD. Post operative infection: prevention and management. In: Rock JA, Thompson JD, editors. Te linde's operative gynecology. sth ed. Philadelphia: Lippincott Raven;1997. p. 233-1.
Di Saia PJ, Walker JL, Gold MA. Perioperative care. In: Scott JR, Di Saia PJ, Hammond CB, Spellacy WN, editors. Danforth's obstetrics & gynecology. 8th ed. Philadelpia: Lippincott Williams & Wilkins;1999. p. 703-8.
Hager WD. Postoperative infection: prevention and management. In: Schwartz SI, Shires GT, Spencer FC, Daly JM, Fischer JE, Galloway AC, editors. Principle of surgery. 7th ed. Singapore: McGraw-Hill;1999. p. 131-3.
Ledger WJ. Current problems in antibiotic treatment in obstetric and gynecology. Rev Infect Disease 1985;7 [suppl 4]: 679-9.
Hirsch HA. Prophylactic antibiotics in obstetrics and gynecology. Am J Med 1985;78 [suppl 6B]: 170-6.
Mittendorf R, Aronson MP, Berry RE, et al. Avoiding serious infections associated with abdominal hysterectomy: a meta-analysis of antibiotic prophylaxis. Am J Obstet Gyn col 1993;169:1119-24.
Tracy JW, Websten LT. Drug used in the chemotherapy of protozoal infection. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG. The pharmacological basic of therapeutics. 9th ed. New York: McGraw-Hilil;1806. p. 995-8.
Clark WG, Brater DC, Johnson AR. Pharmacokinetic characteristic of drug: Gothh's medical pharmacology.13th ed. St. Louis: Mosby Year book;1992. p. 789.
Anderson PO, Knoben JE, Troutman WG. Clinical drug data: miscellancous antimicrobials. sth ed. Stamford: Appleton & Lange;1999. p. 185-7.
Shannon MT, Wilson BA, Stang C. Health professional drug guide: metronidazole. Stamford: Appleton & Lange; 2000. p. 912-5.
ประทักษ์ โอประเสริฐสวัสดิ์. การวิจัยเชิงทดลอง. ใน: รณชัย อธิสุข, ดิฐกานต์ บริบูรณ์หิรัญสาร, พรรณเพ็ญ รัตติกาลสุขะ, บรรณาธิการ. ระเบียบวิจัย. พิมพ์ครั้งที่ 6. กรุงเทพฯ: ราชวิทยาลัยสูตินรีแพทย์แห่งประเทศไทย; 2544. หน้า 312-33.
Popkin DR, Martinez LA, Carswell GA. Metronidazole in the prophylaxis of anaerobic infections in gynecologic surgery. Surgery 1993; 93: 180-4.
Dhar KK, Dhall GI, Ayyagari A. Tinidazole prophylaxis in elective abdominal hysterectomy. Int J Gynaecol Obstet 1993;42:121-5.
Henriksson L, Frick G, Kullander S, Sandholm LE, Ursing J, Cederberg A. Metronidazole prophylaxis to prevention infection after total abdominal hysterectomy. Acta Obstet Gynecol Scand 1998;77:116-19.
Hamsell DL, Reisch J, Nobles B, Hamsell PG. Prevention of major infection after e lective abdominal hysterectomy. Am J Obstet Gynecol 1998;147:520-8.
Vincelette GR, Finkelstein F, Aoki FY, et al. Double blind trial of perioperative intravenous metronidazole prophylaxis for abdominal and vaginal hysterectomy. Surgery 1983;93(1pt 2):185-9.
Evaldson GR, Lindgren S, Malberg AS, Nord
CE. Single dose intravenous tinidazole prophylaxis in abdominal hysterectomy. Acta Obstet Gynecol Scand 1986;65:361-5.
Sutthjumroon S, Chandeying V, Tungphaisal S. Efficacy of cefoxitin in the prevention of postoperative infection in abdominal hysterectomy. Asia Oceania J Obstet Gynecol 1990;16:347-51.
สัมพันธ์ พันธุ์ทิพย์แพทย์, เมธา ทรงธรรมวัฒน์, ศรีสุดา ไทยเลิศ. การใช้ยาปฏิชีวนะเพื่อป้องกันการติดเชื้อในการผ่าตัดมดลูกทางหน้าท้องที่โรงพยาบาลอุดรธานี. วารสารการแพทย์เครือข่าย 6/2 2541:5:13-22.
อำนวย ตัณฑ์ศุภศริ, ระพี เฉลิมวุฒานนท์. ภาวะไข้ภายหลังการฝ่าตัดมดลูกทางหน้าท้องในโรงพยาบาลราชวิถี.วารสารโรงพยาบาลราชวิถี 2542;10:45-56.
Shackelf DP, Hoffman MK, Davies MF, Kaminski PF. Predictive value for infection of febrile morbidity after vaginal surgery. Obstet Gynecol 1999;93:928-31.